Jasper Therapeutics GAAP EPS of -$1.13 beats by $0.08

* Jasper Therapeutics press release [https://seekingalpha.com/pr/20300411-jasper-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate] (JSPR [https://seekingalpha.com/symbol/JSPR]): Q3 GAAP EPS of -$1.13 beats by $0.08.
* Cash and cash equivalents as of September 30, 2025, totaled $50.9 million.
* Research and development expense for the three months ended September 30, 2025, was $14.4 million.
* General and administrative expense for the three months ended September 30, 2025, was $4.8 million.

MORE ON JASPER THERAPEUTICS

* Seeking Alpha’s Quant Rating on Jasper Therapeutics [https://seekingalpha.com/symbol/JSPR/ratings/quant-ratings]
* Historical earnings data for Jasper Therapeutics [https://seekingalpha.com/symbol/JSPR/earnings]
* Financial information for Jasper Therapeutics [https://seekingalpha.com/symbol/JSPR/income-statement]